Incyte Genomics Appoints Richard U. De Schutter and Paul A. Brooke to its Board of Directors PALO ALTO, CA, January 14, 2002 - Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomics information company announced today the appointment of Richard U. De Schutter and Paul A. Brooke to its Board of Directors. Richard De Schutter was previously the Chairman and Chief Executive Officer of the DuPont Pharmaceuticals Company. Before assuming this position in 2000, he had been the Vice-Chairman, Chief Administration Officer, and a Director of the Monsanto Company, a leading life sciences company. Prior to his Monsanto appointment, he had been the Chairman and Chief Executive Officer of G.D. Searle & Co., a wholly owned subsidiary of Monsanto engaged in the research, development and marketing of pharmaceutical products since April, 1995. He is also a director of Smith & Nephew Plc., and Varian Inc. Paul Brooke is currently the General Partner of PMSV Holdings LLC. He is also an Advisory Director of Morgan Stanley and a Venture Partner of MPM Capital. Previously, he was a Managing Director at Morgan Stanley and Global Head of Healthcare Research and Strategy. Mr. Brooke has served as a Board Member of the Morgan Stanley Venture Fund, and he currently serves on the board of WebMD, ViroPharma and a number of privately held companies. "We are pleased that Mr. Brooke and Mr. De Schutter have joined our Board of Directors," said Paul A. Friedman, M.D., Chief Executive Officer of Incyte. "Both of these men bring the experience and commitment to facilitate Incyte's build-up of an effective therapeutic discovery organization that will complement Incyte's successful information business." Incyte Genomics, Inc. has developed the leading integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, related reagents and services. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. In addition, Incyte has the largest portfolio of issued United States patents covering human full-length genes and the proteins they encode and is leveraging its intellectual property position to be a leader in therapeutic discoveries. For more information, visit Incyte's web site at http://www.incyte.com. Except for the historical information contained herein, the matters set forth in this press release, including without limitation statements as to the future development of its therapeutic discovery organization, the ability of Incyte's products and services to enhance the research efforts of, and provide value to, its customers, and Incyte's ability to leverage its intellectual property position to become a leader in therapeutic discoveries, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the ability of Incyte to provide products and services that meet market needs and that beat other substantially similar products and services to market; the impact of competition and the ability of Incyte to compete against competitors that may have greater financial and other resources; the availability of the financial resources necessary to fund Incyte's business objectives; changes in the business plan of Incyte; Incyte's ability to obtain patent protection for its discoveries and to continue to be effective in expanding its patent coverage; and other risks detailed from time to time in Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2001. Incyte disclaims any intent or obligation to update these forward-looking statements.